Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

From the category archives: OBN News

Partnering Announcements

Celleron Therapeutics enters into a license agreement with Roche to improve the lives of patients living with tenosynovial giant cell tumour

Oxford, UK:  Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the signing of a licensing agreement with Roche providing Celleron exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab. The closing is expected by end of 2020 after all conditions have been met.   This license agreement of emactuzumab demonstrates Celleron’s commitment to cancer medicine development and its transformational potential for patients inflicted with cancer. Emactuzumab is a monoclonal antibody designed to target and deplete macrophages in the tumor tissue. It has shown a favourable safety profile in patients and very encouraging efficacy for diffuse tenosynovial giant cell tumour (TGCT), a rare disease characterised by the proliferation of macrophages in the synovial tissue in the joint and tendon sheath.   Professor Nick La Thangue, Chief Executive Officer of Celleron Therapeutics, com ...

Read the rest of entry »

ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19

Foster City, Calif., and Nottingham, UK:  ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials. Laboratory experiments have shown niclosamide stops SARS-CoV-2 (the virus that causes COVID-19) from replicating, making it a promising candidate for reducing the spread of COVID-19. Niclosamide was previously approved by the FDA as a treatment for tapeworm and although not currently marketed in the U.S., it is on the World Health Organization’s List of Essential Medicines and has been used for decades to ...

Read the rest of entry »

Physiomics Enters Contract with Astellas

Physiomics awarded contract by Astellas Pharma Inc. Oxford, UK:  Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that, further to its announcements of 27 May, 30 June and 22 July 2020, it has been awarded a contract by a new client, Astellas Pharma Inc. (TSE: 4503) (“Astellas”), a Japanese global pharmaceutical company. The contract is for a modelling project involving Physiomics’ Virtual Tumour™ immuno-oncology model and relates to an undisclosed Astellas asset.  The work is expected to be completed this calendar year.  The precise value of the contract cannot be disclosed for reasons of commercial confidentiality however it is around 20% of the Company’s last full year’s total income to the 30 June 2019. Dr Jim Millen, CEO said: “We are delighted to have ...

Read the rest of entry »

Evox Therapeutics Announces a Multi-Target RNA Interference and Antisense Research Collaboration and License Agreement With Lilly

Evox Therapeutics Announces a Multi-Target RNA Interference and Antisense Research Collaboration and License Agreement With Lilly

Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders.

Read the rest of entry »

Ethypharm and RSSL partnership fast-tracks priority medicine

Respected scientific and regulatory advisor, Nigel Baldwin, has partnered with RSSL to provide context and guidance on analytical data for new food ingredient submissions.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.